- Datum04.03.2026
- Uhrzeit13:00 - 14:00 Uhr
- Veranstalter
stock3
Aclaris Therapeutics Inc. Chart inkl. Chartanalyse
Charts analysieren
wie die Profis?
Nutze unser Profi-Charting-Tool für Deine eigenen Analysen
Chart analysieren
Realtime-Kurs
| Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Tradegate BSX | VK | |||||
| Stuttgart | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
-0,82 %
Intraday
-9,96 %
1 Woche
-12,93 %
1 Monat
0,66 %
Seit Jahresbeginn
54,59 %
1 Jahr
-76,29 %
3 Jahre
-86,21 %
5 Jahre
-82,52 %
10 Jahre
Passender Service zu Aclaris Therapeutics Inc.
Webinar zu Aclaris Therapeutics Inc.
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)1,050-4,890
- Jahrestief / Hoch ($)---
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Aclaris Therapeutics Inc.
Keine Dividenden verfügbar
Termine von Aclaris Therapeutics Inc.
- Mai12Aclaris Therapeutics Inc.Q1 2026 Earnings Release
- Aug12Aclaris Therapeutics Inc.Q2 2026 Earnings Release
- Nov11Aclaris Therapeutics Inc.Q3 2026 Earnings Release
Beschreibung
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
